CMPX COMPASS THERAPEUTICS INC

Compass Therapeutics to Participate in Upcoming Investor Events

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2023.

Details are as follows:

Stifel Healthcare Conference

Location: New York, NY

Date: Tuesday, November 14, 2023

Time: 9:45am EST

Webcast Link:

Jefferies London Healthcare Conference

Location: London, U.K.

Date: Thursday, November 16, 2023

Time: 2:30pm GMT (9:30 EST)

Webcast Link:

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’  page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at .

Investor Contact

Media Contact

Anna Gifford, Communications Manager



617-500-8099



EN
07/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMPASS THERAPEUTICS INC

 PRESS RELEASE

Compass Therapeutics Announces Pricing of Upsized $120 Million Public ...

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2...

 PRESS RELEASE

Compass Therapeutics Announces Proposed Public Offering

Compass Therapeutics Announces Proposed Public Offering BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compas...

 PRESS RELEASE

Compass Therapeutics Reports 2025 Second Quarter Financial Results and...

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in pat...

 PRESS RELEASE

Compass Therapeutics to Present Second Quarter Financial Results and P...

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025 BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Cal...

 PRESS RELEASE

Compass Therapeutics to Participate in the Jefferies Global Healthcare...

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat DetailsDate: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link:  Virtual/Replay availability: The fireside chat will be archived for 90 days on Co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch